{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T09:53:11Z","timestamp":1774605191693,"version":"3.50.1"},"reference-count":9,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Keratin-positive giant cell-rich tumor (KPGCT) is a rare bone and soft tissue neoplasm, with pediatric and metastatic cases being exceedingly uncommon.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Observation:<\/jats:title>\n                    <jats:p>\n                      We report a 1.5-month-old male infant presenting with multifocal metastatic disease involving the skull, adrenal glands, vertebrae, mandible, soft tissue, and long bones. Histopathologic evaluation confirmed KPGCT, molecular testing was negative for\n                      <jats:italic toggle=\"yes\">HMGA2<\/jats:italic>\n                      rearrangement. Treatment with imatinib resulted in marked regression of lesions and clinical improvement without toxicity.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>\n                      This case expands the clinical spectrum of pediatric KPGCT and suggests that imatinib may be an effective treatment option in infants with advanced disease, even canonical\n                      <jats:italic toggle=\"yes\">HMGA2::NCOR2<\/jats:italic>\n                      fusion absent.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/mph.0000000000003177","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T18:00:10Z","timestamp":1773338410000},"page":"148-152","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Keratin-Positive Giant Cell-Rich Tumor in Early Infancy: Metastatic Presentation and Imatinib Response"],"prefix":"10.1097","volume":"48","author":[{"given":"Cem","family":"\u00c7anak\u00e7i","sequence":"first","affiliation":[{"name":"Pediatric Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2863-901X","authenticated-orcid":false,"given":"Sonay","family":"\u0130ncesoy \u00d6zdemir","sequence":"additional","affiliation":[{"name":"Pediatric Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1015-6784","authenticated-orcid":false,"given":"Handan","family":"Din\u00e7aslan","sequence":"additional","affiliation":[{"name":"Pediatric Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melda","family":"Berber Hamamci","sequence":"additional","affiliation":[{"name":"Pediatric Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nihal","family":"Ekin Da\u011f","sequence":"additional","affiliation":[{"name":"Pediatric Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1274-2920","authenticated-orcid":false,"given":"Vafa","family":"Maharramova","sequence":"additional","affiliation":[{"name":"Pediatric Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6602-0643","authenticated-orcid":false,"given":"Nubar","family":"Mustafayeva","sequence":"additional","affiliation":[{"name":"Pediatric Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7750-1781","authenticated-orcid":false,"given":"Nur Ay\u00e7a","family":"\u00c7elik","sequence":"additional","affiliation":[{"name":"Pediatric Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6835-8709","authenticated-orcid":false,"given":"Koray","family":"Ceyhan","sequence":"additional","affiliation":[{"name":"Pathology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seda","family":"Kaynak \u015eahap","sequence":"additional","affiliation":[{"name":"Radiology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0180-0013","authenticated-orcid":false,"given":"Suat","family":"Fit\u00f6z","sequence":"additional","affiliation":[{"name":"Radiology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8776-6604","authenticated-orcid":false,"given":"Can Berk","family":"Leblebici","sequence":"additional","affiliation":[{"name":"Medical Genetics, Faculty of Medicine, Ankara University, Ankara, T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2999-4745","authenticated-orcid":false,"given":"N\u00fcket","family":"Kutlay","sequence":"additional","affiliation":[{"name":"Medical Genetics, Faculty of Medicine, Ankara University, Ankara, T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nurdan","family":"Ta\u00e7yildiz","sequence":"additional","affiliation":[{"name":"Pediatric Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2026,2,24]]},"reference":[{"key":"R2-20260327","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1038\/ng.2814","article-title":"Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone","volume":"45","author":"Behjati","year":"2013","journal-title":"Nat Genet"},{"key":"R3-20260327","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1073\/pnas.0507321103","article-title":"A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells","volume":"103","author":"West","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"R4-20260327","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1038\/s41379-021-00789-8","article-title":"Recurrent novel HMGA2-NCOR2 fusions characterize a subset of keratin-positive giant cell-rich soft tissue tumors","volume":"34","author":"Agaimy","year":"2021","journal-title":"Mod Pathol"},{"key":"R5-20260327","doi-asserted-by":"crossref","first-page":"163","DOI":"10.21873\/cgp.20312","article-title":"Recurrent fusion of the genes for high-mobility group AT-hook 2 (HMGA2) and nuclear receptor co-repressor 2 (NCOR2) in osteoclastic giant cell-rich tumors of bone","volume":"19","author":"Panagopoulos","year":"2022","journal-title":"Cancer Genomics Proteomics"},{"key":"R6-20260327","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1038\/s41379-022-01115-6","article-title":"Xanthogranulomatous epithelial tumors and keratin-positive giant cell-rich soft tissue tumors: two aspects of a single entity with frequent HMGA2-NCOR2 fusions","volume":"35","author":"Dehner","year":"2022","journal-title":"Mod Pathol"},{"key":"R7-20260327","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1097\/PAS.0000000000002051","article-title":"Giant cell tumors with HMGA2::NCOR2 Fusion\u202f: clinicopathologic, molecular, and epigenetic study of a distinct entity","volume":"47","author":"Perret","year":"2023","journal-title":"Am J Surg Pathol"},{"key":"R8-20260327","doi-asserted-by":"crossref","first-page":"e2300659","DOI":"10.1200\/PO.23.00659","article-title":"Keratin-positive giant cell tumor of bone and soft tissue with HMGA2::NCOR2 fusion in children under 10 with response to imatinib therapy: a case series","volume":"8","author":"Rungsiprakarn","year":"2024","journal-title":"JCO Precis Oncol"},{"key":"R9-20260327","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.3390\/cancers16101940","article-title":"Keratin-positive giant cell-rich tumor: a review and update","volume":"16","author":"Nishio","year":"2024","journal-title":"Cancers (Basel)"},{"key":"R10-20260327","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s40425-017-0257-y","article-title":"Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy","volume":"5","author":"Cannarile","year":"2017","journal-title":"J Immunother Cancer"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000003177","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T09:00:09Z","timestamp":1774602009000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000003177"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,24]]},"references-count":9,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000003177","relation":{},"ISSN":["1077-4114","1536-3678"],"issn-type":[{"value":"1077-4114","type":"print"},{"value":"1536-3678","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,24]]},"assertion":[{"value":"2025-12-27","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-06","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}